24687-79-4

Usage

Uses

Used in Pharmaceutical Industry:
2-[(3,4-dimethoxybenzyl)amino]ethanol is used as a building block for the synthesis of various drugs due to its unique chemical structure and functional groups, which can be incorporated into medicinal compounds to enhance their therapeutic properties.
Used in Research and Development:
2-[(3,4-dimethoxybenzyl)amino]ethanol serves as a valuable intermediate in the development of new pharmaceuticals and chemical entities, allowing researchers to explore its potential in creating novel drug candidates and understanding its interactions with biological targets.
Used in Specialty Chemicals Production:
2-[(3,4-dimethoxybenzyl)amino]ethanol may also find applications in the production of specialty chemicals, where its specific properties can be leveraged to create high-value products for niche markets. The exact applications and uses can vary depending on the industry requirements and the specific context in which the compound is utilized.

Upstream product

• 120-14-9 3,4-dimethoxy-benzaldehyde 
• 141-43-5 ethanolamine 
• 37771-28-1 2-(3,4-dimethoxy-benzylideneamino)-ethanol 

Downstream Products

• 3576-63-4 dichloro-acetic acid-[(2-hydroxy-ethyl)-veratryl-amide] 
• 24687-77-2 N-methyl-N-veratryl-aethanolamin 
• 18713-10-5 N-Veratryl-aethanolamin-N-tosylat 

Relevant academic research and scientific papers

An Alternative Approach to the Hydrated Imidazoline Ring Expansion (HIRE) of Diarene-Fused [1.4]Oxazepines

A four-step approach to the “hydrated imidazoline ring expansion” (HIRE) is presented. In most cases, the ring expansion was the sole process. However, for the first time, an alternative course of the hydrated imidazoline evolution was discovered which gave N-aminoethyl derivatives. These can, in principle, be converted into the target HIRE products under sufficiently forcing conditions. The approach offers improved flexibility with respect to the peripheral substituents and is also applicable to the synthesis of eleven-membered lactams. We observed that the latter can exist in two stable isomeric forms due to lactam–amide bond isomerization. The latter finding further demonstrates the value of medium-sized rings as multiple-conformer probes for biological target interrogation.

Structural studies on bioactive compounds. 34.1 Design, synthesis, and biological evaluation of triazenyl-substituted pyrimethamine inhibitors of Pneumocystis carinii dihydrofolate reductase

The triazenyl-pyrimethamine derivative 3a (TAB), a potent and selective inhibitor of Pneumocystis carinii DHFR, was selected as the starting point for a lead optimization study. Molecular modeling studies, corroborated by a recent crystal structure determination of the ternary complex of P. carinii DHFR-NADPH bound to TAB, predicted that modifications to the acetoxy residue of the lead inhibitor could exploit binding opportunities in the vicinity of an active site pocket bounded by residues Ile33, Lys37, and Leu72. Substitutions in the benzyl moiety with electron-donating and electron-withdrawing groups were predicted to probe face-edge interactions with amino acid Phe69 unique to the P. carinii enzyme. New triazenes 10a-v and 12a-f were prepared by coupling the diazonium tetrafluoroborate salt 6b of aminopyrimethamine with substituted benzylamines or phenethylamines. The most potent of the new inhibitors against P. carinii DHFR was the naphthylmethyl-substituted triazene 10t (IC50: 0.053 μM), but a more substantial increase in potency against the rat liver DHFR led to a reduction in selectivity (ratio rat liver DHFR IC50/P. carinii DHFR IC50: 5.36) compared to the original lead structure 3a (ratio rat liver DHFR IC50/P. carinii DHFR IC50: 114).